Merck known as MSD outside of the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for ENFLONSIA™ (clesrovimab-cfor) to expand its indication to...
Injection is bioequivalent and therapeutically equivalent to the reference listed drug, BRIDION®2 Injection, 100 mg/mL of Merck Sharp & Dohme LLC [NDA 022225]. According to IQVIA® sales data for the 12-month period ending May 2026, the BRIDION®...
Merck, a leading global science and technology company, announced that the European Commission (EC) approved an update to the Erbitux (cetuximab) EU label on June 26, 2026. Erbitux is now indicated in combination with encorafenib for patients with...
Merck known as MSD outside of the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) to include children and...
Merck known as MSD outside of the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) approved IDVYNSO™, a new, two-drug single-tablet regimen of 100 mg doravirine and 0.25 mg islatravir, for the treatment of HIV-1...
Merck known as MSD outside of the United States and Canada, and Eisai today announced the first presentation of results from the Phase 3 LITESPARK-011 trial evaluating the dual oral regimen of WELIREG® (belzutifan). Merck’s first-in-class oral...
Merck known as MSD outside of the United States and Canada, announced positive second RSV season findings from the Phase 3 SMART trial (MK-1654-007) (NCT04938830) evaluating the safety, efficacy and pharmacokinetics of ENFLONSIA™ (clesrovimab) in...
and Orkambi for cystic fibrosis. Earlier in his career, he held positions of increasing responsibility in DMPK at Merck Research Laboratories. Dr. Dean received his Ph.D. in medicinal chemistry from the State University of New York, Buffalo, and...
Merck known as MSD outside of the United States and Canada, announced positive topline results from the Phase 3 LITESPARK-022 trial in patients with clear cell renal cell carcinoma (RCC) following nephrectomy. In this study, KEYTRUDA®...
antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed by Daiichi Sankyo and Merck (NYSE: MRK), known as MSD outside of the United States and Canada. SCLC is aggressive and progresses rapidly to the...
to a FDA Breakthrough Device Designation for INBRAIN’s BCI-Tx in Parkinson’s Disease. In collaboration with partners like Merck KGaA and our subsidiary INNERVIA Bioelectronics, we are expanding these innovations to treat peripheral nerve and...
that has been studied in early and metastatic breast cancer patients with an inherited BRCA mutation. AstraZeneca with Merck & Co., Inc. (known as MSD outside the US and Canada) continue to research olaparib in these settings and to explore its...
MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, and Opentrons Labworks, Inc., a leader in lab automation and accessible robotics, announced a multi-year agreement to automate assay kits on a custom...
parallel, Hanmi is also conducting a Phase 1 trial to assess the safety and efficacy of BH3120 in combination with MSD's (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in patients with advanced or metastatic solid...
has licensed its PD-1 new molecular entity (NME) to LaNova Medicines, which recently entered into an agreement with Merck to advance treatment. LaNova Medicines leveraged ProBio's PD-1 molecule to develop its PD-1/VEGF bispecific antibody, a key...
MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, announced that the company’s Life Science business achieved EXCiPACT cGMP (current Good Manufacturing Practice) certification for Pharmaceutical Auxiliary...
